TY - JOUR T1 - Scientific letter: A double-blind, randomised, placebo-controlled, 3-month crossover trial of night-time oxygen therapy in advanced systolic heart failure JF - Heart JO - Heart SP - 1468 LP - 1469 DO - 10.1136/heartjnl-2012-302719 VL - 98 IS - 19 AU - Joseph L Blackshear AU - Robert Safford AU - Paul Fredrickson AU - Colleen Thomas AU - Michael Heckman AU - Malik Al-Omari AU - Joseph Kaplan Y1 - 2012/10/01 UR - http://heart.bmj.com/content/98/19/1468.abstract N2 - To the Editor: Three unblinded studies of night-time oxygen in patients with Cheyne Stokes Respirations and congestive heart failure (CSR-CHF) showing subjective improvements in exercise capacity, and New York Heart Association Classification versus parallel controls, and an increase in left ventricular ejection fraction of between 5% and 10%,1–3 were undertaken. On the basis of these studies, it was found that home oxygen therapy is in widespread use and is covered by national insurance in Japan, but is not sanctioned by international CHF guidelines. Respiratory-based therapies are subject to placebo effect, and oxygen is no exception.4 Amid concern regarding the inadequacy of the scientific basis for the prescription of night-time oxygen therapy, two additional trials in the UK (ISRCTN60260702) and Australia (ACTRN12609000103268) are in early enrolment. In discussing these ongoing studies, a tepid recommendation for the use of night-time oxygen was stated. … ER -